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Respiratory failure, driven by bacterial infection, leads to mortality in the majority
of cystic ﬁbrosis (CF) patients, with irreversible loss of lung function occurring
principally during periods of infective exacerbation. The bacterial species present in
the CF airways are increasingly well-characterised. However, comparatively little is
known about the dynamics of the bacteria in the CF lung. If a link between bacterial
dynamics and patient condition could be established, such information could be of
profound clinical impact. The aim of this study was to determine the level to
which the bacterial community varies over time in individual patients and whether
clinical status was correlated to these changes. Sputum samples were collected every
2−3 days from adult CF patients during stability and every day during infective
exacerbation. Laboratory data, clinical data, and patient-generated measures of well-
being were recorded. Analysis of bacterial content was carried out with traditional
culture-based assessments and by using culture independent methods. Terminal
Restriction Fragment Length Polymorphism proﬁling of ribosomal regions based
on both DNA and RNA templates, was used to determine bacterial composition.
Bacterial numerical distribution and activity data showed a strong correlation
(r2 >0.8, p< 0.001) between three measures of bacterial assemblage structure and
exacerbation. The signiﬁcance of these ﬁndings in relation to clinical status and
longer term implications for improved treatment are also discussed.
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Background: Although sputum samples are the best non-invasive way to identify
pulmonary organisms in CF, as patients clinical status improves, we have an
increasing group of adults who do not regularly produce sputum. It has been
suggested that cough swabs might give a low yield in these patients: we wished to
study this further in our adult clinic.
Method: Over a 6 month period, cough swabs were taken from all 72 patients who
were unable to produce sputum at their clinic visit. Prior to sampling, all patients
completed 3 cycles of Active Cycle of Breathing Technique (ACBT) in the sitting
position before the cough swab sample was taken by the same physiotherapist
(EL). Organisms subsequently identiﬁed were compared with those previously
isolated from each individual: 45 (63%) were known to be chronically infected
by Pseudomonas aeruginosa (35 with the Liverpool Epidemic Strain (LES) and
10 with unique strains). The remainder (37%) did not regularly grow organisms,
including Staphylococcus aureus.
Results: Of those known to be chronically infected, 38 swabs (84%) cultured
Pseudomonas aeruginosa: 32 in the LES group and 6 in the unique group (91% and
60% respectively), with the remaining swabs (16%) growing normal oropharyngeal
ﬂora only. In those 27 without chronic infection, the cough swabs revealed normal
oropharyngeal ﬂora in 23 (85%), Haemophilus parainﬂuenza in 1 (4%), and no
growth in the remainder (11%).
Conclusions: This study shows that, in those patients who cannot easily produce
sputum, correctly taken cough swabs following a period of physiotherapy can
produce a high yield of organisms that are representative of the patients’ pulmonary
ﬂora. It is recommended that this technique is adopted when attempting to obtain
microbiological samples from non-expectorating adult patients.
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The identiﬁcation of microbial species from respiratory specimens and their sus-
ceptibility to antimicrobial agents belong to the most important diagnostic measures
of CF care. Under the umbrella of EuroCareCF two quality assurance trials on CF
microbiology were performed in 2007 and 2008. For each trial ﬁve formulations
with CF bacterial isolates were despatched. 31/37 laboratories from 18/21 Euro-
pean countries participated in the 2007/2008 trials. The common CF pathogens
Pseudomonas aeruginosa and Staphylococcus aureus were correctly identiﬁed by
almost all participants in both trials even if the strains presented uncommon
phenotypes. Burkholderia cenocepacia IIIB and Burkholderia vietnamensis CF
isolates, however, were correctly assigned at the species level by only 26% and
27% of the laboratories. Emerging pathogens such as Achromobacter xylooxydans,
Inquilinus limosus or Pandorea pnomenusa were also not detected or misclassiﬁed
by many laboratories. Two participants correctly identiﬁed all CF isolates in both
trials. Of 23 determinations of antimicrobial susceptibility in the second trial, the
percentage of correct classiﬁcations (susceptible, intermediate, resistant) ranged
from 73–100% (median: 98%) per isolate and drug. Each trial presented information
about the CF patients’ history and clinical status when the specimens had been taken
for bacteriological analysis. Participants were asked to assess the impact of emerging
pathogens for CF lung disease and to provide recommendations for antimicrobial
chemotherapy and infection control measures. In the second trial most answers
reﬂected the current state of the art.
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Objectives: to know the distribution of Burkholderia cepacia complex (Bcc) species
isolated from various samples (maize, corn, potatoes, onions, artichoks. . . ) within
an agricultural area around the cystic ﬁbrosis center of Roscoff in French western
Brittany and to evaluate the epidemiological signiﬁcance.
Methods: 207 plants (roots, leaves) and soil were collected throughout the 2007
growing season between may and september. The B. cepacia-like colonies grown
on a semiselective PCAT medium were then subcultured onto a selective BCSA
medium. Each B. cepacia-like colonies were screened with a Bcc-speciﬁc 16S rDNA
gene-based PCR assay. Positive Bcc isolates were identiﬁed to the species level
using a combination of Ampliﬁed Ribosomal rDNA restriction analysis (ARDRA)
and recA analysis.
Results: 383 of B. cepacia-like colonies picked up from BCSA medium were
screened for molecular identiﬁcation, 139 isolates were positive with the speciﬁc
16S rDNA assay, 11 isolates could not be subcultured. Among the 128 isolates
identiﬁed with ARDRA and recA analysis, four proﬁles could be identiﬁed:
B. graminis (73 strains), B. cenocepacia (38), B. multivorans (9) and a fourth
one unknown (8). B. multivorans was more frequently isolated from maize roots,
B. cenocepacia IIIA from corn roots and B. cenocepacia IIIB from potatoes.
Conclusion: among the vegetables and cereals analyzed, B. cenocepacia and
B. multivorans that are associated with clinical infections in patients with cystic
ﬁbrosis, were rather found in maize, corn and potatoes.
Supported by: Vaincre la Mucoviscidose (2006–2007).
